Oryzon Genomics: Taking on epigenetics
Biopharmaceutical company Oryzon Genomics has named Roger Bullock its Chief Medical Officer. He will be responsible for executing the clinical development plan of the epigenetic drugs developed by the company.
Bullock graduated in Physiological Sciences at Keble College in Oxford University and got his MB.BS at London University. He specialised in Old Age medicine and in neurodegenerative and neuropsychiatric disorders. He has extensive experience as clinical researcher, having participated in more than 70 clinical trials in Alzheimers disease and other CNS conditions. Over his 30-year research career, he has authored and co-authored more than 100 peer-reviewed publications and book chapters in this domain and presented at numerous conferences. Recently he has been working as a consultant for companies active in the CNS space, including Lilly and Merck.
With the appointment of Bullock, César Molinero will transition from his current dual position as Chief Medical and Clinical Operations Officer to concentrate on the role of Chief Clinical Officer.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium